Clinical Trial

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This single-arm trial will explore the efficacy and safety of long-course neoadjuvant chemoradiation with liposomal irinotecan and capecitabine guided by UGT1A1 status in patients with locally advanced rectal cancer.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-04
notable Primary completion moved earlier: 2026-02-01 -> 2025-09-30 2026-08-04
Trial Details
NCT Number NCT06210971
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Rectal Cancer
Enrollment 60 participants
Start Date 2024-02-01
Primary Completion 2025-09-30 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-03